Medi-Mibi (Tetrafluoroborate)

Medi-Mibi contains tetrafluoroborate, which is currently not associated with a specific therapeutic pathway or disease family.

• No established indication: currently not approved for a specific clinical condition.
• Research use only: may be utilized in investigational protocols under controlled settings.
• Diagnostic adjunct: occasionally employed in experimental imaging or laboratory assays.

• The precise pharmacological mechanism of tetrafluoroborate when administered intravenously has not been fully elucidated. It is believed to interact with ionic pathways and may influence cellular electrolyte balance, but detailed target receptors or signaling cascades remain undefined in the scientific literature.

Adverse reactions to tetrafluoroborate are not well characterized in the public domain.

Common Side Effects

• Mild infusion site irritation: localized redness or discomfort at the injection site.
• Transient headache: short‑lasting headache during or after infusion.
• Nausea: occasional feeling of nausea without vomiting.

Serious or Rare Side Effects

• Hypotension: significant drop in blood pressure requiring monitoring.
• Allergic reaction: rash, itching, or swelling that may indicate hypersensitivity.
• Renal impairment: potential impact on kidney function in susceptible individuals.
• Cardiac arrhythmia: irregular heart rhythm observed in rare cases.

When handling Medi-Mibi, consider the following precautions:

• Patient assessment: evaluate cardiovascular and renal status before infusion.
• Infusion monitoring: observe vital signs throughout administration.
• Compatibility check: ensure solution compatibility with IV fluids and lines.
• Contraindication review: avoid use in patients with known hypersensitivity to tetrafluoroborate.
• Emergency preparedness: have resuscitation equipment ready for severe reactions.
• Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Potential drug interactions with tetrafluoroborate have not been comprehensively documented.

Major Interactions (Avoid)

• Strong electrolytes: concurrent high‑dose potassium or calcium may alter ionic balance.
• Anticoagulants: risk of bleeding when combined with warfarin or heparin.

Moderate Interactions (Monitor Closely)

• Diuretics: may affect fluid and electrolyte status.
• Nephrotoxic agents: monitor renal function when used with aminoglycosides or NSAIDs.